May 1st 2024
The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.
Pegcetacoplan shows increasing beneficial effects after 30 months of continuous treatment for GA
August 2nd 2023Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).